Codexis Reports Fourth Quarter and Fiscal Year 2025 Financial Results

Why It Matters

The results show Codexis scaling its enzymatic manufacturing platform, turning technology wins into meaningful revenue growth while securing a multi‑year cash runway, positioning the firm for broader commercial adoption in the oligonucleotide market.

Key Takeaways

• FY2025 revenue up 19% to $70.4M.
• Q4 revenue surged 81% to $38.9M.
• Merck deal contributed $37.8M technology transfer.
• Cash runway extends through 2027.
• ECO Synthesis platform gains pharma and CDMO partners.

Pulse Analysis

Codexis’ FY 2025 financials underscore a turning point for the enzyme‑based biotech firm. Revenue rose to $70.4 million, propelled by a landmark $37.8 million technology‑transfer agreement with Merck that lifted product gross margin to 64% and narrowed the net loss to $44 million. The quarter‑over‑quarter surge to $38.9 million in Q4 reflects accelerating demand for Codexis’ enzymatic solutions, while disciplined cost management reduced SG&A expenses, delivering a modest Q4 profit of $9.6 million.

Beyond the numbers, Codexis is leveraging its proprietary ECO Synthesis® platform to reshape RNAi manufacturing. The company demonstrated the ability to produce 10‑gram and 3‑kilogram siRNA batches enzymatically, a scale previously unattainable with traditional chemistry. Partnerships with over 40 firms, three CDMOs, and a new GMP‑ready facility slated for kilogram‑scale output signal growing confidence in the technology. Recent breakthroughs in stereoisomer control further differentiate Codexis, promising enhanced therapeutic potency and regulatory appeal as the FDA’s Emerging Technologies team evaluates product comparability.

Looking ahead, Codexis’ cash position of $78.2 million secures operations through 2027, supporting its roadmap to commercial launches and strategic licensing deals. The 2026 revenue outlook of $72‑$76 million aligns with anticipated expansion of CDMO collaborations and the ramp‑up of its GMP site. If the company can translate its platform advantages into clinical‑stage manufacturing agreements, it could capture a sizable share of the rapidly expanding oligonucleotide market, positioning itself as a critical enabler for next‑generation gene‑silencing therapies.